Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions

By Yujun Tong, Xiaobing Fan, Huan Liu, Tiantian Liang. 2024

Subfields: Drug Discovery, Oncology, Pharmacology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “…(ADC) such as Sacituzumab govitecan which links a humanized anti-TROP2 monoclonal antibody to the topoisomer-ase-I inhibitor SN-38, enabling targeted cytotoxic delivery in metastatic triple-negative breast cancer and metastatic hormone receptor-positive/HER2-negative breast cancer (16 – 19).”